IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Two Sigma Advisers LP

Two Sigma Advisers LP increased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 206.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 108,600 shares of the medical research company's stock after purchasing an additional 73,200 shares during the quarter. Two Sigma Advisers LP owned approximately 0.06% of IQVIA worth $25,735,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Opal Wealth Advisors LLC bought a new position in IQVIA in the second quarter worth approximately $27,000. Capital Performance Advisors LLP bought a new position in IQVIA in the third quarter worth approximately $27,000. Park Place Capital Corp bought a new position in IQVIA in the third quarter worth approximately $28,000. Itau Unibanco Holding S.A. bought a new position in IQVIA in the second quarter worth approximately $29,000. Finally, International Assets Investment Management LLC bought a new position in IQVIA in the second quarter worth approximately $32,000. Institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

IQV has been the subject of a number of analyst reports. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They set a "buy" rating and a $276.00 target price for the company. Barclays lowered their target price on IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Truist Financial lowered their target price on IQVIA from $286.00 to $265.00 and set a "buy" rating for the company in a report on Monday, November 4th. TD Cowen decreased their price objective on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a report on Friday, November 1st. Finally, Robert W. Baird decreased their price objective on IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $256.50.

IQVIA Stock Performance

IQV traded up $2.70 during midday trading on Friday, hitting $202.63. 1,388,125 shares of the company were exchanged, compared to its average volume of 2,002,141. The company's 50 day simple moving average is $215.18 and its 200 day simple moving average is $225.11. The firm has a market capitalization of $36.78 billion, a price-to-earnings ratio of 26.59, a price-to-earnings-growth ratio of 2.09 and a beta of 1.49. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.